DOCSLIB.ORG

New Medicines Committee Briefing July 2015 Avanafil (Spedra®) 50Mg, 100Mg and 200Mg Oral Tablets for Treatment of Erectile Dysfunction in Adult Males

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Medicines Committee Briefing July 2015 Avanafil (Spedra®) 50Mg, 100Mg and 200Mg Oral Tablets for Treatment of Erectile Dysfunction in Adult Males New Medicines Committee Briefing: Avanafil July 2015 New Medicines Committee Briefing July 2015 Avanafil (Spedra®) 50mg, 100mg and 200mg oral tablets for treatment of erectile dysfunction in adult males. Avanafil® is to be reviewed for use Primary Care within: Secondary Care Summary: Avanafil (Spedra®) is an oral PDE5 inhibitor for erectile dysfunction There is currently no oral alternative to sildenafil listed in the Joint Formulary Avanafil would provide an alternative to sildenafil and could be used for patients who fail first line sildenafil There are no head to head trials of avanafil vs alternative PDE5 inhibitor; meta analyses provide some evidence that avanafil is likely to be as effective as other PDE5 inhibitors Avanafil has a 15 minute onset of action compared to sildenafil’s 1 hour onset Department of Health restrictions on prescribing will limit the use of avanafil to certain patient groups and/or specialist clinics Avanafil is significantly more expensive than generic sildenafil (e.g. £3.52 vs 29p per dose at typical treatment dosage) and similarly priced to other branded PDE5 inhibitors. Formulary application Consultant submitting application: Mr Samson Liu (Consultant Urological Surgeon) Supported by: Mr A Golash, Mr L Gommersall, Mr C Luscombe, Mr Mark Saxby, Mr H Fernando, Mr RL James and Mr YR Rao (Consultant Urological Surgeons) with Mr H Nair (Associate Specialist in Urology) and Dr VS Chadalavada (Clinical Assistant in Urology) Clinical Director supporting application: Miss A Walsh (Clinical Director for General Surgery and Urology) The application is a request for avanafil to be considered for inclusion in the North Staffordshire Joint Formulary for the treatment of erectile dysfunction in adult males. Page 1 of 10 Written by David Prayle New Medicines Committee Briefing: Avanafil July 2015 In support, the applicant states that avanafil is well suited for the on demand treatment of mild to severe erectile dysfunction and: is effective in men with erectile dysfunction, including those with diabetes and nerve sparing radical prostatectomy has been shown to be generally well tolerated over 52 weeks demonstrates long term tolerability and improvement in sexual function and has rapid onset of action Mr Liu estimates that 200 new patients will be treated per year with avanafil at a cost of £167.28 per patient and that the treatment will be long term. Avanafil provides a second line option for patients who have failed sildenafil. The application states that the new drug cost will be accompanied by a reduction in the use of currently prescribed PDE5 inhibitor erectile dysfunction drugs – ether generic sildenafil or nonformulary tadalafil and vardenafil. Background Erectile dysfunction (ED) is defined as the consistent or recurrent inability to achieve and/or maintain an erection sufficient to permit satisfactory sexual performance. Normal erectile function requires the coordination of psychological, hormonal, neurological, vascular and anatomic factors. Alteration of any of these is sufficient to cause ED. The main causes of ED are chronic systemic illnesses (diabetes mellitus, heart disease, hypertension and peripheral vascular disease), neurological disorders (post- traumatic spinal-cord injuries, multiple sclerosis) or post-surgical lesions (after radical prostatectomy)1. The European guidelines on male sexual dysfunction2 advise that first‑line therapy is usually oral treatment with selective phosphodiesterase type 5 (PDE5) inhibitors (e.g. sildenafil). NICE guidelines on multiple sclerosis3, type 1 diabetes4, type 2 diabetes5 and myocardial infarction6 advise that men with erectile dysfunction should be offered PDE5 inhibitors. Men with prostate cancer should have early and ongoing access to specialist erectile dysfunction services7. The majority of drug treatments for erectile dysfunction may only be prescribed on the NHS under certain circumstances. In addition, the Department of Health recommends that treatment should also be available from specialist services when the condition is causing severe distress. Following a consultation, in June 20148, the Department of Health has amended the regulations to allow unrestricted prescribing of generic sildenafil for men with erectile dysfunction. Avanafil has been added to the list of treatments for erectile dysfunction that are still restricted including tadalafil, vardenafil, branded sildenafil and alprostadil. Avanafil (brand name Spedra®), a new PDE5 inhibitor, is licensed for the treatment of erectile dysfunction in adult men9. The product received a European Marketing Authorisation for the treatment of erectile dysfunction in adult men in June 2013 and was launched in the UK in March 2014. Current formulary status Avanafil is not listed in the current North Staffordshire Joint Formulary. The drugs listed for erectile dysfunction are listed in the table, below (colour codes added in text) 7.4.5 Drugs for erectile dysfunction Alprostadil (Caverject®) Green MTRAC Alprostadil (MUSE®) Green MTRAC Apomorphine Green Sildenafil Green MTRAC Therapeutic class and mode of action9 Avanafil is a highly selective and potent, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by avanafil produces increased levels of cGMP in the corpus cavernosum of Page 2 of 10 Written by David Prayle New Medicines Committee Briefing: Avanafil July 2015 the penis. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Licensed indication Treatment of erectile dysfunction in adult men. In order for Spedra® (avanafil) to be effective, sexual stimulation is required. Dosage and administration The recommended dose is 100 mg taken as needed approximately 15 to 30 minutes before sexual activity. Based on individual efficacy and tolerability, the dose may be increased to a maximum dose of 200 mg or decreased to 50 mg. The maximum recommended dosing frequency is once per day. Sexual stimulation is required for a response to treatment. Avanafil has not been evaluated in patients with erectile dysfunction due to spinal cord injury or other neurological disorders and in subjects with severe renal or hepatic impairment. Safety and adverse effects9 Contraindications Hypersensitivity to the active substance or to any of the excipients The use of avanafil is contraindicated in: Patients who are using any form of organic nitrate or nitric oxide donors (such as amyl nitrite) Patients who have suffered from a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; Patients with resting hypotension (blood pressure < 90/50 mmHg) or hypertension (blood pressure > 170/100 mmHg); Patients with unstable angina, angina with sexual intercourse, or congestive heart failure categorised as New York Heart Association Class 2 or greater. Patients with severe hepatic impairment (Child-Pugh C). Patients with severe renal impairment (creatinine clearance < 30 mL/min). Patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous type 5 phosphodiesterase (PDE5) inhibitor exposure. Patients with known hereditary degenerative retinal disorders. Patients who are using potent CYP3A4 inhibitors (including ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir and telithromycin) Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease before prescribing avanafil. Adverse Events The safety profile of avanafil is based on 2436 subjects exposed to avanafil during the clinical development program. The most common adverse reactions reported in clinical studies were headache, flushing, nasal and sinus congestion and back pain (≥ 1/100 to < 1/10). Overall adverse events and adverse reactions for avanafil-treated subjects were more frequent in subjects with a Body Mass Index (BMI) <25 (normal BMI subjects). In the long term clinical study, the percentage of patients who experienced adverse reactions decreased with increasing length of exposure. Page 3 of 10 Written by David Prayle New Medicines Committee Briefing: Avanafil July 2015 Drug Interactions Potential for pharmacodynamic interactions with avanafil Nitrates - administration with any form of organic nitrate or nitric oxide donor (such as amyl nitrite) is contraindicated. Alpha-blockers - in patients receiving stable doxazosin treatment, mean maximum decreases in standing and supine systolic blood pressure following avanafil dosing were 2.5 mmHg and 6.0 mmHg, respectively. In patients receiving stable tamsulosin treatment, mean maximum decreases in standing and supine systolic blood pressure following avanafil dosing were 3.6 mmHg and 3.1 mmHg, respectively Antihypertensives other than alpha-blockers - mean maximum decrease in supine blood pressure of 2/3 mmHg with enalapril and 1/-1 mmHg with amlodipine. Amlodipine increases the maximum and total exposure of avanafil by 28% and 60%, respectively. Alcohol - concurrent use of avanafil and alcohol may increase the likelihood of hypotension, dizziness, or syncope. The safety and efficacy of combinations of avanafil and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied. Effects of other substances
Load more

Recommended publications
  • WO 2017/048702 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
    [Show full text]
  • Penile Injection Therapy | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Penile Injection Therapy This information will help you learn to inject medication into your penis. This is called penile injection therapy. Penile injections can help you achieve an erection if you have erectile dysfunction (ED). Read this resource carefully before starting injection therapy. If you do not follow the instructions in this resource, your doctor or APP may stop prescribing your penile injection medications and supplies. About Penile Injection Therapy The tissue that causes you to get an erection (erectile tissue) is a muscle. Going long periods of time without an erection is unhealthy for erectile tissue and may damage it. We believe having erections keeps erectile tissue healthy. A penile injection helps you have an erection. It works best if it’s given about 5 to 15 minutes before you want an erection. Penile Injection Therapy 1/19 Giving Yourself the Injection Your advanced practice provider (APP) will review the instructions below with you. Generally, the training for the injections takes 2 office visits. Please be aware that each visit may take up to 1 hour, so you should plan your schedule on the day of your appointment. Use this resource to help you the first few times you inject on your own. Do not take the following medications within 18 hours of injecting (before or after): Sildenafil (Viagra®) - 20 mg to 100 mg Vardenafil (Levitra®) - 10 mg to 20 mg Avanafil (Stendra®) - 50 mg to 200 mg If you take tadalafil (Cialis®) 10 mg or 20 mg, do not inject within 72 hours (3 days) of taking the medication.
    [Show full text]
  • Call for Methods
    CALL FOR METHODS Methods for Identification, Determination, or Screening Methods for PDE5 Inhibitors AOAC INTERNATIONAL invites method developers to submit methods for consideration and possible evaluation through the AOAC Official MethodsSM program. Prospective methods may be qualitative, identification methods, and/or screening methods for phosphodiesterase type 5 inhibitors (PDE5 inhibitors) in dietary ingredients and supplements. OBJECTIVE: The objective of this call for methods is to select and evaluate methods that can be used for routine surveillance of dietary ingredients. Acceptable methods must be reliable and reproducible when used by trained analysts in accredited laboratories. Interested method developers should provide a description of their proposed method and data characterizing the analytical performance of the proposed method. For the purpose of this Call-for-Methods, PDE5 inhibitors are defined as avanafil, lodenafil carbonate, mirodenafil, sildenafill, tadalafil, udenafil, or vardenafil; or any of their analogs. Any analytical technique that measures the analytes of interest and meets the method performance requirements specified in the SMPR will be considered. It is acceptable to have a different analytical method for each class of analytes. Applicable SMPRs: • View AOAC 2014.010 – Methods for the Identification of PDE5 Inhibitors • View AOAC SMPR 2014.011 – Methods for the Determination of PDE5 Inhibitors • View AOAC SMPR 2014.012 – Screening Methods for PDE5 Inhibitors Submit Your Method AOAC INTERNATIONAL METHOD SUBMISSION PROCESS: AOAC invites method authors to submit their methods with no fee required. Interested method authors or developers should provide a copy of their proposed method, as well as any available data characterizing the analytical performance and scientific validity of the method in AOAC format.
    [Show full text]
  • Gastroesophageal Reflux Disease (GERD)
    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Can PDE Inhibition Improve Cognition? : Translational Insights
    Can PDE inhibition improve cognition? : Translational insights Citation for published version (APA): Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht University. https://doi.org/10.26481/dis.20130418or Document status and date: Published: 01/01/2013 DOI: 10.26481/dis.20130418or Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
    [Show full text]
  • Package Leaflet: Information for the User Norvir 100 Mg Film-Coated Tablets Ritonavir Read All of This Leaflet Carefully Before
    Package leaflet: Information for the user Norvir 100 mg film-coated tablets ritonavir Read all of this leaflet carefully before you start taking this medicine because it contains important information for you or your child. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Norvir is and what it is used for 2. What you need to know before you or your child takes Norvir 3. How to take Norvir 4. Possible side effects 5. How to store Norvir 6. Contents of the pack and other information 1. What Norvir is and what it is used for Norvir contains the active substance ritonavir. Norvir is a protease inhibitor used to control HIV infection. Norvir is used in combination with other anti-HIV medicines (antiretrovirals) to control your HIV infection. Your doctor will discuss with you the best combination of medicines for you. Norvir is used by children 2 years of age or older, adolescents and adults who are infected with HIV, the virus which causes AIDS. 2. What you need to know before you or your child takes Norvir Do not take Norvir if you are allergic to ritonavir or any of the other ingredients of Norvir (see section 6).
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 2 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 2 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Clinical Pharmacology of Phosphodiesterase 5 Inhibitors in Erectile Dysfunction
    SOA Archives of Pharmacy & Pharmacology Review Article Clinical Pharmacology of Phosphodiesterase 5 Inhibitors in Erectile Dysfunction This article was published in the following Scient Open Access Journal: SOA Archives of Pharmacy & Pharmacology Received September 20, 2018; Accepted October 01, 2018; Published October 08, 2018 Michel Bourin* Abstract Department of pharmacology, University of Nantes, 98, rue Joseph Blanchart 44100 Nantes, France The drugs active on erectile dysfunction in humans are now mainly phosphodiesterase 5 inhibitors, those that are marketed are Sildenafil, Vardefanil, Taladafil, and Avanafil. We propose a synthesis of the pharmacological, pharmacokinetic and clinical properties of these derivatives. We have also listed their most common side effects and their potential drug interactions. Keywords: Phosphodiesterase 5 inhibitors, Sildenafil, Vardefanil, Taladafil, Avanafil. Introduction Phosphodiesterase 5 (PDE 5) inhibitors are a type of targeted therapy used to treat people with pulmonary hypertension (PH) [1]. Targeted therapies slow the progression of PH and may even reverse some of the damage to the heart and lungs. There are two typesPDE of PDE5 inhibitors 5 inhibitor are currentlyalso used usedto treat to treat erectile PH: dysfunction sildenafil, tadalafil [3]. This [2]. is because the body has the same type of cells in the blood vessels of the lungs as the blood vessels of the penis. Viagra (sildenafil) has been used to treat erectile problems since 1998. to obtain or maintain an erection. These problems are common and can be solved effectivelyIn case byof erectileconsulting dysfunction a doctor itand is essential following to a determine suitable treatment. the cause ofUnless the difficulties there are more serious causes of erectile dysfunction, the recommended treatment will usually be a PDE5 inhibitor.
    [Show full text]
  • Drug Consumption in Current Year (Period 201901
    Page 1 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A ALIMENTARY TRACT AND METABOLISM 323,80 3 4 321 589 7 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01AA Caries prophylactic agents 11,90 3 14 663 8 9 A01AA01 sodium fluoride 11,90 3 14 610 8 10 A01AA03 olaflur - - - 53 1 -2 A01AB Antiinfectives for local oral treatment 2,36 8 2 1 266 10 15 A01AB03 chlorhexidine 2,02 6 -3 930 6 5 A01AB11 various 0,33 21 57 335 21 55 A01AB22 doxycycline - - - 0 - -100 A01AC Corticosteroids for local oral treatment - - - 113 1 -26 A01AC01 triamcinolone - - - 113 1 -26 A01AD Other agents for local oral treatment 0,02 0 -28 49 0 -32 A01AD02 benzydamine 0,02 0 -28 49 0 -32 A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 3 30 885 4 -5 A02A ANTACIDS 2,23 1 1 3 681 1 3 A02AA Magnesium compounds 0,07 22 -7 141 22 -7 A02AA04 magnesium hydroxide 0,07 22 -7 141 22 -7 A02AD Combinations and complexes of aluminium, 2,17 0 1 3 539 0 4 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 1 3 539 0 4 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 3 27 205 5 -7 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 -77 551 10 -29 A02BA02 ranitidine 0,00 1 -100 1 1 -100 A02BA03 famotidine 0,16 7 48 550 10 43 A02BB Prostaglandins 0,04 62 55 80 62 55 A02BB01 misoprostol 0,04 62 55 80 62 55 A02BC Proton pump inhibitors 69,26 3 4 23 531 4 -8
    [Show full text]
  • Effect of Phosphodiesterase- Type 5 Inhibitors on Erectile Function: an Overview of Systematic Reviews and Meta- Analyses
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2020-047396 on 24 August 2021. Downloaded from Effect of phosphodiesterase- type 5 inhibitors on erectile function: an overview of systematic reviews and meta- analyses Nikolaos Pyrgidis ,1,2 Ioannis Mykoniatis,1,2 Anna- Bettina Haidich ,3 Maria Tirta,2 Persefoni Talimtzi,3 Dimitrios Kalyvianakis,1,2 Andreas Ouranidis,4 Dimitrios Hatzichristou1,2 To cite: Pyrgidis N, Mykoniatis I, ABSTRACT Strengths and limitations of this study Haidich A- B, et al. Effect of Introduction Phosphodiesterase- type 5 inhibitors phosphodiesterase- type 5 (PDE5i) are the recommended first- line treatment for ► We will provide the first overview exploring the use inhibitors on erectile function: an erectile dysfunction. Previous systematic reviews and overview of systematic reviews of phosphodiesterase- type 5 inhibitors (PDE5i) for meta- analyses suggest that they are a safe and effective and meta- analyses. BMJ Open the treatment of erectile dysfunction. option in many patient groups. Similarly, PDE5i may be 2021;11:e047396. doi:10.1136/ ► We will assess, in a holistic approach, the safety and effective as part of combination therapy in non- responders bmjopen-2020-047396 efficacy of PDE5i. to PDE5i. We will generate an overview of systematic ► We will evaluate the quality and the strength of ► Prepublication history and reviews, meta- analyses and network meta- analyses evidence deriving from systematic reviews, meta- additional supplemental material aiming to summarise the available knowledge regarding for this paper are available analyses and network meta-analyses in an attempt the efficacy and safety of PDE5i in the general population online. To view these files, to affect clinical and policy decisions.
    [Show full text]